• darkblurbg

    Towards a cure for type 1 diabetes

    Antigen based therapies
    Medical Technology
    Stem Cells

  • Diabetes

    More than 400 million people worldwide suffer from diabetes. 10-20% have an autoimmune form of the disease where the immune system attacks and destroys the insulin-producing beta cells. Autoimmune diabetes is a chronic disease and there is currently no cure.

  • Product Development

    Diamyd Medical develops the diabetes vaccine Diamyd®, based on the exclusively licensed GAD molecule. The Company’s licensed technologies GABA and Gliadin also have the potential to become key pieces of the puzzle to prevent, treat or cure autoimmune diabetes.

  • Clinical Trials

    The development of Diamyd Medical’s licensed technologies for GAD, GABA and Gliadin, in combination or with other substances with various mechanisms of action, is carried out in clinical trials and preclinical studies. Six clinical trials are currently ongoing.


Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq Stockholm First North (ticker: DMYD B)

Read More
  Quarterly Report 3, June 2016

Dear Shareholders

It was with great pride and humility that I took over the role of CEO of Diamyd Medical nearly two months ago. This has been an intense period and I recently returned from the American Diabetes Association’s (ADA) 76th Scientific Sessions in New Orleans, the world’s largest diabetes conference, with more than 16,000 delegates. The principal message for the type 1 diabetes field was clear: combination therapy and innovative studies are the key to preventing and curing the disease. Government players in the US are showing increasing...

Diamyd Medical is at the very leading edge of the type 1 diabetes field, with clinical studies that are in line with what leading experts see as the future of this area.
Ulf Hannelius, President and CEO